270 related articles for article (PubMed ID: 22493246)
1. The activity of Gli transcription factors is essential for Kras-induced pancreatic tumorigenesis.
Rajurkar M; De Jesus-Monge WE; Driscoll DR; Appleman VA; Huang H; Cotton JL; Klimstra DS; Zhu LJ; Simin K; Xu L; McMahon AP; Lewis BC; Mao J
Proc Natl Acad Sci U S A; 2012 Apr; 109(17):E1038-47. PubMed ID: 22493246
[TBL] [Abstract][Full Text] [Related]
2. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.
Ling J; Kang Y; Zhao R; Xia Q; Lee DF; Chang Z; Li J; Peng B; Fleming JB; Wang H; Liu J; Lemischka IR; Hung MC; Chiao PJ
Cancer Cell; 2012 Jan; 21(1):105-20. PubMed ID: 22264792
[TBL] [Abstract][Full Text] [Related]
3. Epicatechin-rich cocoa polyphenol inhibits Kras-activated pancreatic ductal carcinoma cell growth in vitro and in a mouse model.
Siddique HR; Liao DJ; Mishra SK; Schuster T; Wang L; Matter B; Campbell PM; Villalta P; Nanda S; Deng Y; Saleem M
Int J Cancer; 2012 Oct; 131(7):1720-31. PubMed ID: 22190076
[TBL] [Abstract][Full Text] [Related]
4. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
5. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
[TBL] [Abstract][Full Text] [Related]
6. IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis.
Rajurkar M; Dang K; Fernandez-Barrena MG; Liu X; Fernandez-Zapico ME; Lewis BC; Mao J
Cancer Res; 2017 Jan; 77(2):320-329. PubMed ID: 28069799
[TBL] [Abstract][Full Text] [Related]
7. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
9. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation.
Nolan-Stevaux O; Lau J; Truitt ML; Chu GC; Hebrok M; Fernández-Zapico ME; Hanahan D
Genes Dev; 2009 Jan; 23(1):24-36. PubMed ID: 19136624
[TBL] [Abstract][Full Text] [Related]
10. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma.
Zhang W; Nandakumar N; Shi Y; Manzano M; Smith A; Graham G; Gupta S; Vietsch EE; Laughlin SZ; Wadhwa M; Chetram M; Joshi M; Wang F; Kallakury B; Toretsky J; Wellstein A; Yi C
Sci Signal; 2014 May; 7(324):ra42. PubMed ID: 24803537
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells.
Ji Z; Mei FC; Xie J; Cheng X
J Biol Chem; 2007 May; 282(19):14048-55. PubMed ID: 17353198
[TBL] [Abstract][Full Text] [Related]
12. Hes1 plays an essential role in Kras-driven pancreatic tumorigenesis.
Nishikawa Y; Kodama Y; Shiokawa M; Matsumori T; Marui S; Kuriyama K; Kuwada T; Sogabe Y; Kakiuchi N; Tomono T; Mima A; Morita T; Ueda T; Tsuda M; Yamauchi Y; Sakuma Y; Ota Y; Maruno T; Uza N; Uesugi M; Kageyama R; Chiba T; Seno H
Oncogene; 2019 May; 38(22):4283-4296. PubMed ID: 30705405
[TBL] [Abstract][Full Text] [Related]
13. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo.
Qiu W; Sahin F; Iacobuzio-Donahue CA; Garcia-Carracedo D; Wang WM; Kuo CY; Chen D; Arking DE; Lowy AM; Hruban RH; Remotti HE; Su GH
Oncotarget; 2011 Nov; 2(11):862-73. PubMed ID: 22113502
[TBL] [Abstract][Full Text] [Related]
14. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma.
Ju HQ; Ying H; Tian T; Ling J; Fu J; Lu Y; Wu M; Yang L; Achreja A; Chen G; Zhuang Z; Wang H; Nagrath D; Yao J; Hung MC; DePinho RA; Huang P; Xu RH; Chiao PJ
Nat Commun; 2017 Feb; 8():14437. PubMed ID: 28232723
[TBL] [Abstract][Full Text] [Related]
15. Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia.
Shi G; DiRenzo D; Qu C; Barney D; Miley D; Konieczny SF
Oncogene; 2013 Apr; 32(15):1950-8. PubMed ID: 22665051
[TBL] [Abstract][Full Text] [Related]
16. Ciliogenesis and Hedgehog signalling are suppressed downstream of KRAS during acinar-ductal metaplasia in mouse.
Bangs FK; Miller P; O'Neill E
Dis Model Mech; 2020 Jul; 13(7):. PubMed ID: 32571902
[TBL] [Abstract][Full Text] [Related]
17. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
[TBL] [Abstract][Full Text] [Related]
18. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes.
Mueller S; Engleitner T; Maresch R; Zukowska M; Lange S; Kaltenbacher T; Konukiewitz B; Öllinger R; Zwiebel M; Strong A; Yen HY; Banerjee R; Louzada S; Fu B; Seidler B; Götzfried J; Schuck K; Hassan Z; Arbeiter A; Schönhuber N; Klein S; Veltkamp C; Friedrich M; Rad L; Barenboim M; Ziegenhain C; Hess J; Dovey OM; Eser S; Parekh S; Constantino-Casas F; de la Rosa J; Sierra MI; Fraga M; Mayerle J; Klöppel G; Cadiñanos J; Liu P; Vassiliou G; Weichert W; Steiger K; Enard W; Schmid RM; Yang F; Unger K; Schneider G; Varela I; Bradley A; Saur D; Rad R
Nature; 2018 Feb; 554(7690):62-68. PubMed ID: 29364867
[TBL] [Abstract][Full Text] [Related]
19. RelA: a tale of a stitch in time.
Korc M
J Clin Invest; 2016 Aug; 126(8):2799-801. PubMed ID: 27454293
[TBL] [Abstract][Full Text] [Related]
20. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression.
Ijichi H; Chytil A; Gorska AE; Aakre ME; Fujitani Y; Fujitani S; Wright CV; Moses HL
Genes Dev; 2006 Nov; 20(22):3147-60. PubMed ID: 17114585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]